A matter of priority: equitable access to COVID-19 vaccines by Holzer, Felicitas et al.








A matter of priority: equitable access to COVID-19 vaccines
Holzer, Felicitas ; Luna, Florencia ; Manriquez Roa, Tania ; Biller-Andorno, Nikola
Abstract: Over past months, several effective COVID-19 vaccine candidates have been developed in
different countries around the world, with some of them still being in the approval phase. At the same
time, the impossibility of having enough vaccines for everyone in the near future has opened the floor
for a debate about the priority of values and ethical principles that should guide vaccine allocation.
There are, most notably, two main opposing ideas, with several views in between. Some argue that
vaccines should be allocated equitably at the global level, and others claim that it is right and proper
for governments to prioritise populations at the national level. What we currently see is that some
high-income countries (HICs) have launched massive COVID-19 vaccination campaigns, whereas many
low- and middle-income countries (LMICs) will have to wait considerably before immunisation can be
started because of limited access to vaccines. As current data suggest, vaccination has barely started
and progressed in many LMICS, which means that the most vulnerable groups and healthcare workers
remain unprotected (figures 1 and 2). In view of the current situation, it is crucial to address if (at all)
and why wealthier countries should support less affluent populations.
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Over past months, several effective COVID-19 vaccine
candidates have been developed in different countries
around the world, with some of them still being in the ap-
proval phase. At the same time, the impossibility of hav-
ing enough vaccines for everyone in the near future has
opened the floor for a debate about the priority of values
and ethical principles that should guide vaccine allocation.
There are, most notably, two main opposing ideas, with
several views in between. Some argue that vaccines should
be allocated equitably at the global level, and others claim
that it is right and proper for governments to prioritise
populations at the national level. What we currently see
is that some high-income countries (HICs) have launched
massive COVID-19 vaccination campaigns, whereas many
low- and middle-income countries (LMICs) will have to
wait considerably before immunisation can be started be-
cause of limited access to vaccines. As current data sug-
gest, vaccination has barely started and progressed in many
LMICS, which means that the most vulnerable groups and
healthcare workers remain unprotected (figures 1 and 2).
In view of the current situation, it is crucial to address if (at
all) and why wealthier countries should support less afflu-
ent populations.
The view in favour of prioritising populations at the na-
tional level is commonly referred to as “vaccine nation-
alism”. This position encourages governments to use law
and other mechanisms to secure priority access to future
vaccines, for example through Advance Purchase Com-
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Figure 1: Access to vaccines and vaccination policy according to country.
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mitments (APAs) with vaccine manufacturers. APAs are
one way to serve national interest, but at the same time
they erode collaboration between countries (many coun-
tries end up hoarding more vaccines than needed). APAs
have been criticised for lacking transparency and, impor-
tantly, for driving up the prices of vaccine candidates and
related materials as countries start competing against each
other [1].
There is no doubt that global cooperation is necessary
to effectively stop the pandemic. Reducing virus circula-
tion, preventing the spread of new virus mutations, protect-
ing the vulnerable, and ultimately decreasing suffering and
death will only be achieved through strong cooperative ef-
forts at the international level. This insight is well captured
by the slogan “no one is safe until everyone is safe”, which
appeals to a certain degree of self-interest while serving
as a rationale for countries to cooperate at the internation-
al level, and similarly for the World Health Organization
(WHO), United Nations Children’s Fund (UNICEF) and
non-governmental organisations to sustain such coopera-
tion.
The COVAX facility is a recent example of a distributive
scheme to strengthen global cooperation in a way that is
compatible with national interests. It offers access to a
minimum stock of vaccines to all countries, regardless of
their ability to pay [2–5]. Aligned with WHO, the facility
has the goal of distributing vaccines equitably – to LMICs
as well as to HICs – within a global allocation framework,
which is being set up to ensure that persons in especial-
ly vulnerable situations get priority. So far, COVAX’s dis-
tribution framework is conceptualised in a way that coun-
tries pay according to their ability, which later allows them
to access a certain number of doses sufficient to cover up
to 20% of their population. Very poor countries are even
guaranteed access to vaccines without any financial contri-
bution [2–4, 6]. Within this scheme, high priority popula-
tions – especially health workers, high-risk groups and the
elderly – will benefit the most.
Effective control of COVID-19 is not the only goal of CO-
VAX. The facility is also thought to offer a redistribution
mechanism through which especially low-income coun-
tries get access to vaccines that would otherwise be unaf-
fordable for them. But rich countries stand to benefit as
well because the facility offers an insurance mechanism:
countries are guaranteed access to a portfolio of successful
vaccine candidates. Thus, if one vaccine fails in devel-
opment, participating countries will still have the option
to obtain other candidates, which ensures that risks are
spread. There is widespread consensus – motivated by sol-
idarity or simple self-interest – that everyone should have
access to a safe and effective COVID-19 vaccine, at least
until herd immunity has been established globally. Still, a
normative discussion needs to identify the actors who have
a duty to contribute towards this goal, that is, HIC govern-
ments, international organisations, the industry and other
stakeholders. It also needs to be discussed how far-reach-
ing these duties are. For instance, can pharmaceutical com-
panies be expected to offer COVID-19 vaccines at produc-
tion costs or to forgo their intellectual property rights all
together? Is a country morally obliged to limit vaccine ac-
cess to high-risk groups, and provide access to other citi-
zens only once high-risk groups have been served global-
ly?
Figure 2: Cumulative COVID-19 vaccination doses administered by country.
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Here, we will focus on the role of governments. “Vaccine
nationalists” would endorse the view that every govern-
ment has a (moral) duty to give priority to its own pop-
ulation before helping citizens abroad. This seems to be
the position of some HICs, which have ordered and hoard-
ed more vaccines than what their current populations need.
This would imply that nation states are allowed to negoti-
ate multiple (and redundant) APAs, and to forgo their par-
ticipation in a redistributive scheme. Wealthier countries
may ex ante enter into bilateral negotiations with the man-
ufacturers to safeguard high quantities of vaccine doses for
their own population, given that global cooperation efforts
under non-ideal circumstances are not guaranteed and that
there is no certainty of the approval and success of all vac-
cines under development.
This is contrasted by the position “vaccine cosmopolitans”
hold, that is, the view of distributive justice for vaccines
according to which citizenship or community membership
is ethically irrelevant. Vaccine cosmopolitans claim that
justice demands that vaccine allocation should be inde-
pendent of the recipients’ national identities and, generally
speaking, associative ties, which implies we ought to find
other (fair) allocation criteria, irrespective of borders. Most
notably, such criteria will prioritise supply to countries ac-
cording to their need (considering, e.g., the rate of deaths
and infections) or will allocate vaccines in proportion to
the size of a country’s population [7–9]. Cosmopolitans
may differ in their vision of fair distribution principles,
but agree that any allocation principle ought to give equal
consideration to individuals independently of their national
ties. Translating this view into allocation models, “vaccine
cosmopolitans” would most likely support global alloca-
tion mechanisms, such as COVAX, and morally condemn
(excessive) bilateral agreements made by affluent coun-
tries.
Just as cosmopolitanism comes in different shades, nation-
alism, too, exists in stronger and weaker forms. An inter-
mediary nationalist position may, for instance, argue that
limited national partiality in allocating vaccines is not nec-
essarily an obstacle to justice considerations, but can be
part of them [10]. Countries have community-embedded
responsibilities to prioritise their own population. Howev-
er, prioritising one’s own population is not irreconcilable
with the recognition of certain duties towards all persons,
regardless of citizenship and identity. Following this argu-
ment, the question arises of just how much commitment
and self-limitation can be asked from wealthier countries
in order to promote access to vaccines for poorer coun-
tries. Can they buy vaccines for their entire population?
Just enough to get herd immunity, or even less when there
are other countries in much more need? Should there be
caps limiting how much countries can buy through APAs?
Since there is to date no global governance mechanism co-
ordinating or sanctioning non-cooperating countries, dis-
tributive schemes, such as COVAX, can only be imple-
mented as a voluntary cooperative, which implies that
wealthier countries need to be incentivised to join the fa-
cility. Global coordination offered by the COVAX facility
still lacks “teeth”: without a persuasive and solid rationale
for global collaboration, countries prefer to safeguard vac-
cines within bilateral agreements, even when they join CO-
VAX. In the realm of Realpolitik, other options are not
in sight for many countries. So far, only very few vac-
cine doses have been administered in low-income coun-
tries [11]. Many middle-income countries are in a difficult
situation: not poor enough to access vaccines through do-
nations mediated by international health organisations. Al-
though they do not have the purchasing power to get good
deals, they still try to enter in bilateral agreements [1].
Figure 3: Invitation to the Forum for Global Health Ethics: Equitable Access to COVID-19 Vaccines (online event ‒ click here to join the event,
password 621417. No registration needed.)
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Defining who should have access to vaccines first and
why is a complex, important and pressing task. We need
to publicly debate what we mean by “equitable access”
to COVID-19 vaccines, whether the prioritisation of indi-
viduals should take place at a global level or be decided
by countries, and what allocation criteria and mechanisms
should look like. Although vaccine allocation will have
to start before consensus has been reached, such debates
will contribute to the improvement, legitimation and ac-
ceptance of evolving policies, and will eventually foster
societies’ pandemic resilience.
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